Switching to fingolimod: TRANSFORMS extension study results


REPORT FROM THE 26TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH  IN MS (ECTRIMS), GOTHENBURG, SWEDEN, OCTOBER 13-16, 2010 – TRANSFORMS (Trials assessing injectable interferon vs. fingolimod oral in RRMS) was a phase III trial comparing fingolimod and intramuscular beta-interferon-1a in patients with relapsing-remitting MS (Cohen et al. N Engl J Med 2010; 362: 402-415; updated results in Clinical Developments in Multiple Sclerosis , Neurosens, July 7, 2010). The 12-month study reported annualized relapse rates (ARR) of 0.16 with fingolimod 0.5 mg/day, 0.20 with fingolimod 1.25 mg/day and 0.33 with beta-interferon-1a.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page